News und Analysen
After Gaining 16% Early Last Week, This Marijuana Stock Quickly Kissed It All Goodbye
Few industries, if any, offer the type of growth that legal cannabis can bring to the table, which is a big reason why investors have flocked to marijuana stocks in droves. Many of the largest pot....
3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff
Nearly a year ago, reports surfaced that Pfizer (NYSE: PFE) was considering selling or spinning off its consumer healthcare business. But those were just reports. Nothing happened -- until now.On....
3 Reasons Why Pfizer Investors Will Win With a Consumer Business Sale or Spinoff
Nearly a year ago, reports surfaced that Pfizer (NYSE: PFE) was considering selling or spinning off its consumer healthcare business. But those were just reports. Nothing happened -- until now.On....
These Biotech Stocks Are Pricey, but Investors Can Still Buy Them
Sarepta Therapeutics (NASDAQ: SRPT) and Amicus Therapeutics (NASDAQ: FOLD) are two fast-growing biotech stocks that are trading at price-to-sales multiples north of 50, yet biotech investors may....
This Company Gained 76% in its IPO -- and It Isn't Even a Tech Company
In a sure sign that the biotech bull market is alive and well, Rhythm Pharmaceuticals (NASDAQ: RYTM) raised almost $120 million at $17 per share in its initial public offering on Thursday. In its....
Healthcare: Are These the Best Dividend Stocks to Buy Now?
Demand in the healthcare sector isn't tied as closely to the state of the economy as it is in most other sectors. Because of that, dividend-paying healthcare stocks may offer income investors some....
Healthcare: Are These the Best Dividend Stocks to Buy Now?
Demand in the healthcare sector isn't tied as closely to the state of the economy as it is in most other sectors. Because of that, dividend-paying healthcare stocks may offer income investors some....
Here's Why AnaptysBio Inc. Is Rocketing Higher Today
Shares of AnaptysBio Inc. (NASDAQ: ANAB), a clinical-stage biotech developing novel anti-inflammatory drugs, took flight after the company reported positive data from a clinical trial with its....
Why CRISPR Therapeutics AG Stock Lost Ground in September
According to data from S&P Global Market Intelligence, shares of the gene-editing company CRISPR Therapeutics (NASDAQ: CRSP) dropped by 13.1% in September. CRISPR's poor showing last month....
Better Buy: Biogen Inc. vs. Celgene
Owning either of these large-cap biotech stocks has been a great way to get rich over the past decade. Shares of Celgene Corporation (NASDAQ: CELG) have quadrupled since 2007. Biogen Inc. (NASDAQ:....
Better Buy: Biogen Inc. vs. Celgene
Owning either of these large-cap biotech stocks has been a great way to get rich over the past decade. Shares of Celgene Corporation (NASDAQ: CELG) have quadrupled since 2007. Biogen Inc. (NASDAQ:....
Better Buy: Biogen Inc. vs. Celgene
Owning either of these large-cap biotech stocks has been a great way to get rich over the past decade. Shares of Celgene Corporation (NASDAQ: CELG) have quadrupled since 2007. Biogen Inc. (NASDAQ:....
Why the Bears Are Wrong About Keryx Biopharmaceuticals Stock
I haven't exactly been a bull when it comes to Keryx Biopharmaceuticals (NASDAQ: KERX). For starters, it's not even a biotech company (trying for the old "bait-and-switch" move, eh?). It doesn't....
3 Healthcare Dividend Stocks Ideal for Retirees
What does an ideal investment portfolio look like for retirees? The answer to that question varies based on each individual's financial position and goals. However, nearly every retiree wants to....
3 Healthcare Dividend Stocks Ideal for Retirees
What does an ideal investment portfolio look like for retirees? The answer to that question varies based on each individual's financial position and goals. However, nearly every retiree wants to....
Medicare Is Changing. Here Are 3 Things Investors Need to Know
I recently attended a conference at the prestigious Brookings Institute that was all about Medicare payment reform. The event drew an older crowd, with suit-and-tie attire and coffee that was....
Medicare Is Changing. Here Are 3 Things Investors Need to Know
I recently attended a conference at the prestigious Brookings Institute that was all about Medicare payment reform. The event drew an older crowd, with suit-and-tie attire and coffee that was....
3 Monster Stocks in the Making
Halloween is right around the corner, which makes it the perfect time to look for monster stocks in the making. What are some characteristics these stocks might have? Leading market positions,....
Medicare Is Changing. Here Are 3 Things Investors Need to Know
I recently attended a conference at the prestigious Brookings Institute that was all about Medicare payment reform. The event drew an older crowd, with suit-and-tie attire and coffee that was....
2 Stocks Your Children Will Brag About Someday
While few and far between, some businesses are so strong that they can create wealth for generations. That's why we Fools think it's a worthwhile endeavor to constantly search the markets for....
2 Stocks Your Children Will Brag About Someday
While few and far between, some businesses are so strong that they can create wealth for generations. That's why we Fools think it's a worthwhile endeavor to constantly search the markets for....
Why Viacom, DaVita, and K2M Group Holdings Slumped Today
Monday was a down day on Wall Street, with the Dow, S&P 500, and Nasdaq Composite all giving up between 0.1% and 0.2%. The trading session was relatively quiet on the Columbus Day holiday,....
Here's What Lifted Arena Pharmaceuticals, Inc. Stock in September
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) continued its monster climb this year with a 10% gain in September, according to data from S&P Global Market Intelligence. Preclinical results....
Why K2M Group Holdings Inc. Sank Today
K2M Group Holdings (NASDAQ: KTWO) is down 18.6% at 1:07 p.m. EDT after the company released disappointing preliminary revenue for the third quarter, with revenue up just 6% year over year. The....
The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
Shares of NewLink Genetics (NASDAQ: NLNK), a small-cap clinical-stage drug developer focused on therapies to treat cancer, skyrocketed by 25% in September, according to data from S&P Global....